Log In Sign up
The largest database of trusted experimental protocols

Basic fibroblast growth factor (bfgf)

Manufactured by GoldBio
Visit Supplier
Sourced in Macao

BFGF is a laboratory product that serves as a basic fibroblast growth factor. It is a protein involved in the regulation of cell growth and differentiation.

Automatically generated - may contain errors

Lab products found in correlation

Tms inverted microscope, by Nikon (1 mentions) Ultra low attachment six well plate, by Corning (1 mentions) Epidermal growth factor (egf), by Corning (1 mentions) Streptozotocin (stz), by Merck Group (1 mentions) Heparin sodium solution, by Merck Group (1 mentions) Agarose solution, by Merck Group (1 mentions) B27 supplement, by Thermo Fisher Scientific (1 mentions) Ln229, by American Type Culture Collection (1 mentions) Epidermal growth factor (egf), by GoldBio (1 mentions)

4 protocols using basic fibroblast growth factor (bfgf)

1

Glioblastoma Spheroid Culture

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Briefly, gliomaspheres were generated as previously described [[42] (link), [43] (link), [44] (link)]. U-87 MG and A172 human GBM cells were cultured in serum-free DMEM supplemented with 2% B27 (Gibco by Life Technologies, cat. 12587010), 20 ng/ml epidermal growth factor (EGF) (Sigma-Aldrich, cat. H9644) and 20 ng/ml basic fibroblast growth factor (bFGF) (Gold Biotechnology, cat. 1140-02-100) and maintained at 37 °C in a 95% air, 5% CO2 atmosphere. After 24 h, floating cells were re-seeded in a new 60 mm culture plate, in supplemented serum-free medium and the medium was changed every 2 days. Floating aggregates, known as gliomaspheres were formed within 3–5 days after seeding. For morphological examination, pictures were taken with a Nikon TMS inverted microscope.
Mejía-Rodríguez R., Romero-Trejo D., González R.O, & Segovia J. (2023). Combined treatments with AZD5363, AZD8542, curcumin or resveratrol induce death of human glioblastoma cells by suppressing the PI3K/AKT and SHH signaling pathways. Biochemistry and Biophysics Reports, 33, 101430.
+ Open protocol
+ Expand
2

Culturing Mammosphere-Forming Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
TAZDEP or TAZIND cells were grown in serum-free DMEM/F12 10 ng/ml recombinant human basic fibroblast growth factor (bFGF; Gold Biotechnology, MO) 1:1 media (Gibco, NY) supplemented with EGF (20 ng/mL) and B27 (2%) in ultra-low attachment six-well plates (Corning). The mammospheres were allowed to grow for 5 days. Total mammospheres greater than 100 μm in diameter were counted under a microscope. Each experimental group was performed in triplicate.
Shen H., Chen Y., Wan Y., Liu T., Wang J., Zhang Y., Wei L., Hu Q., Xu B., Chernov M., Frangou C, & Zhang J. (2021). Identification of TAZ-Dependent Breast Cancer Vulnerabilities Using a Chemical Genomics Screening Approach. Frontiers in Cell and Developmental Biology, 9, 673374.
+ Open protocol
+ Expand
3

Subcutaneous Islet Transplantation in Diabetic Rats

Check if the same lab product or an alternative is used in the 5 most similar protocols
Diabetes was rendered in recipient rats by a single intravenous injection of streptozotocin (STZ, 60 mg/kg, Sigma-Aldrich). Diabetes was confirmed by measuring blood glucose levels >400 mg/dl in two consecutive measurements. A prevascularized SC graft bed was prepared by implanting an agarose-basic fibroblast growth factor (bFGF) disc, as described [22 , 54 (link)]. Briefly, a lyophilized agarose disc made from 4.5% agarose solution (Sigma-Aldrich) with bFGF solution [500 μg/ml bFGF (Gold Biotechnology, St. Louis, MO) in saline] and heparin sodium solution [250 μg/ml (Sigma-Aldrich)] was implanted in the dorsal SC site of recipient rats. A week after implantation, a prevascularized capsule had formed around the disc, and the disc was removed through a small opening made on the capsule. Freshly isolated islets were used for SC transplantation. Islets loaded either on an O2 transporter (n=4) or Neg-CTL device (n=4) were transplanted into the space inside of the prevascularized capsule. The capsule opening and skin wound were separately sutured to close, except for the cannula portion of the device penetrating through the opening. These surgical procedures were performed under general anesthesia.
Komatsu H., Cook C.A., Gonzalez N., Medrano L., Salgado M., Sui F., Li J., Kandeel F., Mullen Y, & Tai Y.C. (2018). Oxygen transporter for the hypoxic transplantation site. Biofabrication, 11(1), 015011.
+ Open protocol
+ Expand
4

Glioma Cell Lines and Glioma Stem Cells

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
The human glioma cell lines, LN229 and A172, were obtained from ATCC (Manassas, VA). U251HF glioma cells were kindly provided by Dr. W. K. Alfred Yung (M. D. Anderson Cancer Center, Houston, TX); U251HF-Luc were generated by stably transfecting a firefly luciferase gene under a CMV promoter into U251HF cells and maintained as described with the addition of Geneticin (G418–800μg/ml) for U251HF-Luc cells (23 (link)). GSC2, GSC20, GSC11, GSC23 and GSC811 patient-derived glioma stem cell lines (24 (link)) were kindly provided by Dr. Frederick Lang (M. D. Anderson Cancer Center, Houston, TX) and cultured as neurospheres passaged every 5–7 days in serum-free DMEM/F12 medium containing B-27 Supplement (Life Technologies, Carlsbad, CA), bFGF (FGF2 Gold BioTechnology, St. Luis, MO) and EGF (Gold Bio Technology). Cell lines were authenticated at the University of Arizona Genetics Core (http://uagc.arl.arizona.edu/services/cell-line-authentication-human). Onalespib (AT13387) was purchased from Medkoo Biosciences (Morrisville, NC).
Canella A., Welker A.M., Yoo J.Y., Xu J., Abas F.S., Kesanakurti D., Nagarajan P., Beattie C.E., Sulman E.P., Liu J., Gumin J., Lang F.F., Gurcan M.N., Kaur B., Sampath D, & Puduvalli V.K. (2017). Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(20), 6215-6226.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!